Transplantation
Drug research and approvals for transplantation: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 1,565 studies of transplantation are recruiting on ClinicalTrials.gov, Health Canada has authorized 69 drug trials for it since 2013, FDA has 16 approved and 83 open orphan designations naming it, and the EU has 30 authorised medicines for it.
- Recruiting worldwide: 1,565
- Trials authorized in Canada: 69
- FDA orphan approvals: 16
- EU medicines: 30
- A Single-Center, Prospective Clinical Cohort Study on Perioperative Management, Exposure, Multiorgan Outcomes, and…NCT07946146 · Not reported · Beijing Tsinghua Chang Gung Hospital · starts Oct 22, 2026
- Ph 1 Study Long-acting Interleukin-7, Efineptakin Alfa, to Enhance Immune Reconstitution After PTCyNCT07940738 · Phase 1 · H. Lee Moffitt Cancer Center and Research Institute · starts Dec 1, 2026
- Immune Reconstitution and Clinical Prognosis Following Umbilical Cord Blood TransplantationNCT07936162 · Not applicable · Institute of Hematology & Blood Diseases Hospital, China · starts Oct 16, 2026
- Bone Deterioration After Kidney Transplantation Assessed by DXA and HR-pQCTNCT07935915 · Not reported · Medical University Innsbruck · starts Oct 21, 2026
- Immune Reconstitution Characteristics and Influencing Factors Following Umbilical Cord Blood TransplantationNCT07932054 · Not reported · Institute of Hematology & Blood Diseases Hospital, China · starts Oct 16, 2026
- Naxitamab Enabled Transplant-Free Study in High-Risk NeuroblastomaNCT07932808 · Phase 2 · Giselle Sholler · starts Nov 26, 2026
- Evaluation of the Outcomes of Kidney Biopsies in Deceased Donors in the Emilia-Romagna RegionNCT07932457 · Not reported · IRCCS Azienda Ospedaliero-Universitaria di Bologna · starts Oct 1, 2025
- Clinical Study on CD20 Monoclonal Antibody for Preventing Early EB Virus Activation After Allogeneic Hematopoietic Stem…NCT07929974 · Phase 2 / Phase 3 · The First Affiliated Hospital of Soochow University · starts Nov 1, 2026
- Transarterial Chemoembolization (TACE) and Stereotactic Body Radiation (SBRT) in Patients With Hepatocellular Carcinoma…NCT07924943 · Not applicable · AIO-Studien-gGmbH · starts Jul 28, 2026
| Aug 27, 2026 | A multicenter, phase 3 randomized, active-controlled, open-label study to evaluate the efficacy and safety of tegoprubart compared with tacrolimus in adult…Tegoprubart (AT-1501) | Eledon Pharmaceuticals | Pending |
| Aug 24, 2026 | An adaptive, randomised controlled trial to treat polyomavirus infections (BKPYV) in kidney and kidney-pancreas transplant recipientsGamunex / Igivnex | University of Queensland | Pending |
| Apr 8, 2026 | Expanded antimicrobial prophylaxis to reduce surgical site infections in liver transplant recipientsMeropenem / Vancomycin / Daptomycin / Fluconazole | University Health Network | Ongoing |
| Mar 4, 2026 | An open-label long term extension (LTE) study for felzartamab studies in solid organ transplantFelzartamab | Biogen | Pending |
| Feb 25, 2026 | Advancing transplantation outcomes in childrenNulojix / Rapamune | National Institute of Allergy and Infectious Diseases (Niaid) | Ongoing |
| Jan 6, 2026 | Renal ex vivo SYN002 perfusion to eliminate cmv transmission: a pilot safety trial in kidney transplant recipients. (short title: respect-cmv trial)SYN002 | University Health Network Ajmera Transplant Centre | Pending |
| Nov 26, 2025 | A seamless phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant and safety of…Frexalimab (SAR441344) | Sanofi-Aventis Canada Inc | Ongoing |
| Oct 30, 2025 | A double-blind, placebo-controlled, multicenter, randomized phase 2 trial evaluating the efficacy and safety of felzartamab in recipients of kidney transplants…Felzartamab | Biogen | Ongoing |
| Jun 19, 2025 | A phase 2b, non-randomized, controlled, open-label, extension study to evaluate the persistence of immune response of the adjuvanted rsvpref3 vaccine and the…Bio RSV oa=adj (GSK3844766A) | GSK | Ongoing |
| Apr 16, 2025 | Semaglutide for the prevention of post-transplant diabetes mellitus in kidney transplant recipientsRybelsus (semaglutide) | University Health Network | Ongoing |
| Jun 30, 2026 | TregziFor use in matched donor hematopoietic stem cell transplantation with myeloablative preparative regimen, for hematopoietic and immunologic… | Orca Biosystems, Inc. | Approved |
| Dec 9, 2025 | WaskyraTreatment of pediatric patients aged 6 months and older and adults with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene… | Fondazione Telethon ETS | Approved |
| Jan 21, 2025 | GrafapexIn combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric… | Medac GmbH | Approved |
| Sep 8, 2023 | AphexdaIn combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent… | Ayrmid Pharma Ltd. | Approved |
| Apr 17, 2023 | OmisirgeFor use in adults and pediatric patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood… | Gamida Cell Ltd. | Approved |
| Jul 16, 2021 | PrografProphylaxis of organ rejection in adult and pediatric patients receiving allogeneic kidney transplant, liver transplant, heart transplant,… | Astellas Pharma Global Development, Inc. | Approved |
| Apr 25, 2017 | OpdivoTreatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell… | Bristol-Myers Squibb Company | Approved |
| Feb 22, 2017 | RevlimidTreatment of multiple myeloma (MM), as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) | Celgene Corporation | Approved |
| Jan 26, 2017 | TepadinaIndicated for reducing the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative… | Adienne S.A. | Approved |
| May 17, 2016 | OpdivoTreatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell… | Bristol-Myers Squibb Company | Approved |
| Mar 10, 2016 | EvomelaFor high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma | Acrotech Biopharma LLC | Approved |
| Aug 17, 2015 | AdcetrisTreatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell… | Seagen Inc. | Approved |
| Dec 15, 2008 | Mozobil (r)To enhance mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in… | Genzyme Corporation | Approved |
| Apr 6, 2007 | HepaGam BPrevention of hepatitis B recurrence following liver transplantation in HBsAG-positive liver transplant patients | Cangene Corporation | Approved |
| Feb 4, 1999 | BusulfexFor use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation… | Otsuka Pharmaceutical Company, Ltd | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA